Today, I met with my colleagues from the pharmaceutical industry to discuss how we, together, will negotiate the next pricing scheme for medicines in the NHS.
We must get this right – the outcome of the negotiations for the next pricing scheme will be pivotal to the future of our industry. The ABPI is the Government recognised body negotiating the pricing of branded medicines on behalf of all pharmaceutical companies. The subjects we talked about will have a significant impact on the way we negotiate and, ultimately, the details of the next pricing scheme.
The negotiations proper will not happen until much later in 2012, but we have now established some of the foundations on which to base our thinking and opened up debate about what matters most to industry.
There are five points which I believe must shape our thinking and discussions as we make our first steps towards negotiations:
I would like these points to underpin our approach to the negotiations next year and I believe that today we have taken an important first step in shaping a better future for the development of new innovative medicines in the UK.
Stephen WhiteheadABPI Chief Executive